Alternativen zu Liraglutide

An FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.

Activates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.

An FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.

An FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is included here for reference only, not as a supplement and not auto-recommended.

An investigational ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. Honest appraisal: the phase-2 data are strong and the first phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it is INVESTIGATIONAL and not yet approved as a general weight-loss medicine, has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), and the expected thyroid C-cell class warning and long-term outcomes are unsettled. It is NOT a dietary supplement; listed here for reference only.

An investigational once-weekly injectable GLP-1 and glucagon receptor dual agonist (an oxyntomodulin analogue, IBI362/LY3305677) developed mainly in China by Innovent and Eli Lilly for obesity and type 2 diabetes. Honest appraisal: real phase-2 and phase-3 randomized trials show clinically meaningful weight loss (~12-17% at higher doses) and HbA1c reduction, but the evidence is almost entirely single-region (Chinese) and recent. It was approved in China in 2025 — it is NOT FDA-approved and is not available or approved in the West. It is a prescription drug, not a dietary supplement.

An investigational once-weekly injectable, exendin-based (exenatide-lineage) GLP-1 receptor agonist most famous for the AMPLITUDE-O cardiovascular-outcomes trial — the first to show that an EXENDIN-based (rather than human-GLP-1-based) agonist reduces major adverse cardiovascular events AND kidney-outcome events in high-risk type 2 diabetes. Honest framing: in AMPLITUDE-O (NEJM 2021, n=4,076) efpeglenatide cut MACE by ~27% and a composite kidney outcome by ~32% versus placebo, and across its phase-2/3 program it lowered HbA1c (up to ~1.0-1.2%) and bodyweight (placebo-adjusted up to ~7 kg in obesity without diabetes). BUT it is INVESTIGATIONAL and not FDA-approved or marketed anywhere; the proven benefits are metabolic and cardiorenal (HbA1c, weight, MACE, kidney) — NOT a demonstrated lifespan/longevity outcome. It carries the full GLP-1-class GI side-effect burden (very common dose-dependent nausea, vomiting, diarrhea). It is a prescription-pathway investigational drug, not a dietary supplement, and grey-market 'efpeglenatide' is especially risky.

Supports 300+ enzymatic reactions — critical for sleep, stress response, muscle function, and cognitive health.